Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4351 AL 4365

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

Sengupta U, Nilson AN, Kayed R.

EBioMedicine. 2016 Apr;6:42-49. doi: 10.1016/j.ebiom.2016.03.035. Epub 2016 Apr 5.

The news advances on Alzheimer's disease's therapeutics

Sun HQ, Zhang X, Huang WJ, Chen WW.

Eur Rev Med Pharmacol Sci. 2016 May;20(9):1903-10.

Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies

Amanatkar HR, Papagiannopoulos B, Grossberg GT.

Expert Rev Neurother. 2017 Jan;17(1):7-16. doi: 10.1080/14737175.2016.1194203. Epub 2016 Jun 9.

Aβ immunotherapy for Alzheimer's disease: where are we?

Güell-Bosch J, Montoliu-Gaya L, Esquerda-Canals G, Villegas S.

Neurodegener Dis Manag. 2016 Jun;6(3):179-81. doi: 10.2217/nmt-2016-0006. Epub 2016 May 27.

[Internal consistency and construct validity of the Quality of Life in Alzheimer's Disease (QoL-AD) proxy – a secondary data analysis]

Hylla J, Schwab CG, Isfort M, Halek M, Dichter MN.

Pflege. 2016 Jul;29(4):183-91. doi: 10.1024/1012-5302/a000494. Epub 2016 May 30.

Caloric restriction: beneficial effects on brain aging and Alzheimer's disease

Van Cauwenberghe C, Vandendriessche C, Libert C, Vandenbroucke RE.

Mamm Genome. 2016 Aug;27(7-8):300-19. doi: 10.1007/s00335-016-9647-6. Epub 2016 May 30.

[Disruption of iron homeostasis and relevant pharmacotherapies in Alzheimer’s disease]

Zhao XY, Wang Y, Wang GB, Zhang JJ.

Yao Xue Xue Bao. 2016 Jun;51(6):866-72.

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia

Owen RT.

Drugs Today (Barc). 2016 Apr;52(4):239-48. doi: 10.1358/dot.2016.52.4.2479357.

Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis

Soysal P, Isik AT, Stubbs B, Solmi M, Volpe M, Luchini C, D'Onofrio G, Pilotto A, Manzato E, Sergi G, Schofield P, Veronese N.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1368-1374. doi: 10.1136/jnnp-2016-313660. Epub 2016 Jun 3.

BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides

Choi RJ, Roy A, Jung HJ, Ali MY, Min BS, Park CH, Yokozawa T, Fan TP, Choi JS, Jung HA.

J Ethnopharmacol. 2016 Aug 22;190:219-30. doi: 10.1016/j.jep.2016.06.013. Epub 2016 Jun 5.

Common therapeutic strategies for prion and Alzheimer's diseases

Elezgarai SR, Biasini E.

Biol Chem. 2016 Nov 1;397(11):1115-1124. doi: 10.1515/hsz-2016-0190.

Essential Oils and Pure Volatile Compounds as Potential Drugs in Alzheimer's Disease Therapy: An Updated Review of the Literature

Maggio A, Rosselli S, Bruno M.

Curr Pharm Des. 2016;22(26):4011-27. doi: 10.2174/1381612822666160607065917.

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis

Xiao T, Jiao B, Zhang W, Tang B, Shen L.

CNS Drugs. 2016 Oct;30(10):899-907. doi: 10.1007/s40263-016-0356-1.

Pharmacogenetic considerations in the treatment of Alzheimer's disease

Cacabelos R, Torrellas C, Teijido O, Carril JC.

Pharmacogenomics. 2016 Jun;17(9):1041-74. doi: 10.2217/pgs-2016-0031. Epub 2016 Jun 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias